HEALTH OF WOMAN. 2020.7(153): 23-30; doi 10.15574/HW.2020.153.23
Gorbunova O. V., Goncharuk N. P., Zarichanska H. V., Ermolovich N. A.
Shupyk National Medical Academy of Postgraduate Education MH of Ukraine, Kiev

Pregnancy against the background of bacterial vaginosis is accompanied by a high risk of obstetric and perinatal complications. Therefore, bacterial vaginosis must be treated in pregnant women. Screening and therapy are performed at the beginning of the II or III trimester of pregnancy. The survival of colonies of pathogenic microorganisms in biofilms is significantly increased, so they can remain viable even at high concentrations of antiseptic. The main advantage of using local combined antiseptic agents is the ability to achieve the maximum concentration of the antibiotic exactly in the place of the greatest accumulation of pathogens with the ability to influence biofilms.
The objective: was to compare the efficacy and safety of various regimens of therapy with topical combined drugs (Lynda and Meratin Combi) in pregnant women with bacterial vaginosis.
Materials and methods. The biocenosis of the vagina was investigated in 351 pregnant women in the II trimester. The diagnosis of bacterial vaginosis was established if the patient had any three of the Amsel criteria.
Results. Microbiological screening of the vaginal biocenosis in the II trimester of pregnancy showed that normocenosis among the surveyed was 18.5%; bacterial vaginosis – 31.6%; vulvovaginal candidiasis – 26.5%; aerobic vaginitis – 22.8%, trichomonas vaginitis – 0.6%. Against the background of bacterial vaginosis, the threat of miscarriage, placental dysfunction occurred 6 times more often, anemia and preeclampsia three times more often, gestational pyelonephritis twice more often than in healthy pregnant women.
In most patients, the sensitivity of the vaginal microflora to metronidazole and ornidazole is the same, but depends on the dose of the antiseptic, the sensitivity to miconazole was almost twice as high as to nystatin. This confirms the need for a differentiated selection of antiseptics for local therapy of bacterial vaginosis during pregnancy.
Conclusion. A more rapid dynamics of the disappearance of the main symptoms of bacterial vaginosis and the normalization of the pH of the vaginal secretion were noted after the use of the drug Limenda. In order to prevent relapse of the disease, it is necessary to carry out the second stage of treatment with probiotics to restore its own lactoflora.
Keywords: screening of vaginal biocenosis in the II trimester of pregnancy; complications of pregnancy against the background of bacterial vaginosis; treating bacterial vaginosis during pregnancy; biofilms; sensitivity of the vaginal microflora to antiseptics; topical treatment of bacterial vaginosis; Limenda; Meratin Kombi.

REFERENCES

1. Bohbot M, Vicaut E, Fagnen D, Brauman M. 2010. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. Infect. Dis. Obstet. Gynecol. 11:705692. https://doi.org/10.1155/2010/705692; PMid:20885970 PMCid:PMC2946572

2. Boyko H. 2012. Bacterial vaginosis: a modern view of the problem. Ukrainian medical journal 5(91):91-93.

3. Chebotar I. 2012. Microbial republics and antimicrobial tyranny. StatusPraesens 4(10):21-24.

4. Chembetei Kavitha Kiran, Jithendra Kandati, Munilakshmi Ponugoti. 2017. Prevalence of bacterial vaginosis in preterm and term labour: a one year study.  2017. International Journal of Reproduction, Contraception, Obstetric and Gynecology 6;6. https://doi.org/10.18203/2320-1770.ijrcog20172072

5. Dubinina V, Marchenko A, Lukyanchuk O, Rybin A. 2018. Clinical experience in the use of drugs Meratin and Meratin-combi for the treatment and prevention of bacterial vaginosis. Female doctor 3:39-42.

6. Gillet Е. 2011. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a metaanalysis. BMC Infect. Dis. 11. https://doi.org/10.1186/1471-2334-11-10; PMid:21223574 PMCid:PMC3023697

7. Golyanovsky O, Mehedko V, Budchenko M. 2017. Modern approaches to the treatment of bacterial vaginosis and mixed nonspecific vaginitis. Health Of Woman 8(124):89-95.

8. http://www.ukrstat.gov.ua/

9. https://www.who.int/countries/ukr/ru/

10. Huang Н, Song L, Zhao W. 2013. Effects of probiotics for the treatment of bacterial vaginosis in adult women: a meta-analysis of randomized clinical trials. Arch. Gynecol. Obstet. https://doi.org/10.1007/s00404-013-3117-0; PMid:24318276

11. Instruction for medical use of drug Limenda, Rotapharm. 2015. https://compendium.com.ua/info/251838/limenda/

12. Instruction for medical use of drug Meratin Combi, Mili Healthcare. 2018. https://compendium.com.ua/info/167696/meratin-kombi/

13. Jack D Sobel. 2013. Bacterial vaginosis. Annual Review of Medicine 51:349-356. https://doi.org/10.1146/annurev.med.51.1.349; PMid:10774469

14. Kozachenko A, Teslenko I, Gubsky K, Nudga N, Kovaleva E. 2012. Comparative efficacy of ornidazole and metronidazole in patients with purulent-inflammatory diseases of the abdominal organs. Emergency Medicine 5(44):56-59.

15. Modak Т, Arora P, Agnes C, Ray R, Goswami SP, Das NK. 2011, May 28. Diagnosis of bacterial vaginosis in cases of abnormal vaginal discharge: comparison of clinical and microbiological criteria. J. Infect. Dew Ctries. 5(5):353-360. https://doi.org/10.3855/jidc.1153; PMid:21628811

16. Nitsovich I, Semenyak A. 2016. Features of the course and treatment bacterial vaginosis in pregnant women. Neonatology, surgery and perinatal medicine VI;3(21):61-64. https://doi.org/10.24061/2413-4260.VI.3.21.2016.10

17. Nosenko E, Kaminsky A, Seilova A, Gritsenko S. 2017. Therapy of vaginal dysbiosis with the combined drug Limenda with high doses of intravaginal metronidazole and miconazole in women with infertility who applied for cycles of assisted reproductive technologies. Reproductive health. Eastern Europe 8;1:47-54.

18. Order of the Ministry of Health of Ukraine dated 15.07.2011 №417 "About the organization of outpatient obstetric and gynecological care in Ukraine."

19. Order of the Ministry of Health of Ukraine dated 21.09.2015 №614 "About state registration (re-registration) of drugs (medical immunobiological drugs) and amendments to registration materials".

20. Radzinsky V. 2011. Obstetric aggression. Moscow, Status Piaesens:688.

21. Rakhmatulina M & Plakhova K. 2012. Bacterial vaginosis associated with Atopobium vaginae: modern principles of diagnosis and therapy. Obstetrics and gynecology 3:88-92.

22. Rogovskaya S & Lipova E. 2014. The cervix, vagina, vulva. Physiology, pathology, colposcopy, aesthetic correction. Moscow, Status Piaesens:832.

23. Thaxton J, Sharma S. 2010. Interleukin-10: a multi-faceted agent of pregnancy. Am J Reprod Immunol. 63;6:482-491. https://doi.org/10.1111/j.1600-0897.2010.00810.x; PMid:20163400 PMCid:PMC3628686

24. Thulkar J, Kriplani A, Agarwal N. 2012. A comparative study of oral single dose of metronidazole, tinidazole, secnidazole and ornidazole in bacterial vaginosis. Indian J. Pharmacol. 44(2):243–245. https://doi.org/10.4103/0253-7613.93859; PMid:22529484 PMCid:PMC3326921

25. Voronenko Yu., Shekera O, Vdovichenko Yu, Gorbunova O. at al. 2016. Current issues of obstetrics in the practice of family medicine: 337. Kyiv, Zaslavsky O.